0001193125-24-209920.txt : 20240829 0001193125-24-209920.hdr.sgml : 20240829 20240829161601 ACCESSION NUMBER: 0001193125-24-209920 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240829 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240829 DATE AS OF CHANGE: 20240829 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Artiva Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001817241 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 863614316 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-42179 FILM NUMBER: 241263895 BUSINESS ADDRESS: STREET 1: 5505 MOREHOUSE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 267-4467 MAIL ADDRESS: STREET 1: 5505 MOREHOUSE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 d890088d8k.htm 8-K 8-K
false 0001817241 0001817241 2024-08-29 2024-08-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2024

 

 

Artiva Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-42179   83-3614316

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

5505 Morehouse Drive, Suite 100

San Diego, California 92121

(Address of principal executive offices)

Registrant’s telephone number, including area code: (858) 267-4467

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   ARTV   Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On August 29, 2024, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, regardless of any general incorporation language in any such filing, unless Artiva expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

   

Description

99.1    Press Release, dated August 29, 2024.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Artiva Biotherapeutics, Inc.
By:  

/s/ Fred Aslan

  Fred Aslan, M.D.
  President and Chief Executive Officer

Dated: August 29, 2024

EX-99.1 2 d890088dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

 

  •  

Strong balance sheet with successful completion of upsized $179.0 million initial public offering

 

  •  

Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications

 

  •  

Treated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematous (SLE) without kidney involvement

SAN DIEGO, August 29, 2024 — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent progress.

“Artiva is at an inflection point as we advance AlloNK® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, M.D., Artiva’s Chief Executive Officer. “With two trials in autoimmunity underway, we are focused on the potential of AlloNK® in delivering effective, safe, and accessible cell therapies for patients with devastating autoimmune disease.”

Recent Business Highlights

AlloNK®

 

  •  

Treatment initiated in the first patient in an investigator-initiated basket trial (IIT) exploring AlloNK® in combination with rituximab in patients with rheumatoid arthritis, pemphigus vulgaris, granulomatosis with polyangiitis/microscopic polyangiitis, and SLE. The trial is being conducted by Integral Rheumatology & Immunology Specialists (IRIS), a community rheumatology clinic, demonstrating the potential to bring AlloNK® to patients in a community setting in addition to academic and transplant centers. The study is assessing the safety, tolerability, and clinical activity of AlloNK® (also known as AB-101).

 

  •  

Announced treatment of the first LN patient in Artiva sponsored Phase 1/1b trial in April 2024. To Artiva’s knowledge, this marks the first patient to receive an allogeneic, off-the-shelf NK cell therapy in a U.S. clinical trial for treatment of an autoimmune disease. In the Phase 1/1b trial, AlloNK® will be administered in combination with rituximab or obinutuzumab. The trial was expanded to include patients with SLE without kidney involvement.

 

  •  

Expect to report initial data on autoimmune indications from at least one of the Phase 1/1b trial or the basket IIT in the first half of 2025.

Corporate and Financial Updates

 

  •  

Significantly extended cash runway through the completion of Artiva’s initial public offering (IPO). Strengthened balance sheet with approximately $179.0 million in gross proceeds from the IPO in July 2024, which extends cash runway at least through the end of 2026 and through key clinical data milestones.

Second Quarter 2024 Financial Results

 

  •  

Cash, Cash Equivalents and Short-Term Investments. As of June 30, 2024, Artiva had cash, cash equivalents, and short-term investments of $46.6 million. In addition, Artiva completed its IPO in July 2024 in which it sold 14,920,000 shares of its common stock, including partial exercise of the overallotment option, for gross proceeds of $179.0 million.

 

  •  

Collaboration Revenue. Collaboration revenue was $0 for the three months ended June 30, 2024, compared to $3.5 million for the three months ended June 30, 2023. Revenues in 2023 were related to the Merck Sharpe & Dohme Corp. collaboration which was terminated in October 2023.

 

  •  

Research and Development Expenses. Research and development expenses were $12.3 million for the three months ended June 30, 2024, compared to $11.3 million for the three months ended June 30, 2023.

 

  •  

General and Administrative Expenses. General and administrative expenses were $3.9 million for the three months ended June 30, 2024, compared to $4.1 million for the three months ended June 30, 2023.

 

  •  

Other Income (Expense), net. Other expense, net, was $1.7 million for the three months ended June 30, 2024, compared to other income, net, of $0.5 million for the three months ended June 30, 2023. Other expense, net, for the three months ended June 30, 2024, includes a loss on change in fair value of simple agreements for future equity (SAFEs) of $2.4 million.

 

  •  

Net Loss. Net loss totaled $17.8 million for the three months ending June 30, 2024, as compared to $11.3 million for the three months ending June 30, 2023, with non-cash stock-based compensation expense of $1.5 million and $2.5 million for the three months ended June 30, 2024 and 2023, respectively.

About Artiva Biotherapeutics

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.

Artiva is headquartered in San Diego, California. For more information, please visit https://www.artivabio.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva Biotherapeutics, Inc. (the “Company”) regarding the potential benefits, accessibility, effectiveness and safety of AlloNK®; the Company’s expectations regarding timing and availability of data from the Phase 1/1b trial or the IIT; and the Company’s future

results of operations and financial position, including cash runway. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, including, without limitation, risks inherent in developing product candidates, future results from the Company’s ongoing and planned clinical trials, risks related to conducting clinical trials, including delays in activation of clinical trial sites or in subject enrollment, the Company’s ability to obtain adequate financing to fund its planned clinical trials and other expenses, risks that future clinical trial results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry and future expenditures. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Artiva Biotherapeutics, Inc.

Condensed Balance Sheets

(unaudited)

(in thousands)

 

     June 30,
2024		     December 31,
2023		  

Assets

     

Cash, cash equivalents and short-term investments

    $ 46,556     $ 76,971  

Property and equipment, net

      7,315       8,096  

Operating and financing lease right-of-use assets

      15,420       16,547  

Other assets

      6,621       3,500  
  

 

 

    

 

 

  

Total assets

    $ 75,912     $ 105,114  
  

 

 

    

 

 

  

Liabilities, convertible preferred stock, and stockholders’ deficit

     

Accounts payable and accrued expenses

    $ 7,037     $ 8,631  

Operating and financing lease liabilities

      15,765       16,912  

Simple agreements for future equity (SAFEs)

      27,720       25,100  

Other liabilities

      74       73  
  

 

 

    

 

 

  

Total liabilities

      50,596       50,716  
  

 

 

    

 

 

  

Convertible preferred stock

      216,413       216,413  

Stockholders’ deficit

      (191,097 )      (162,015 ) 
  

 

 

    

 

 

  

Total liabilities, convertible preferred stock, and stockholders’ deficit

    $ 75,912     $ 105,114  
  

 

 

    

 

 

  

Artiva Biotherapeutics, Inc.

Condensed Statements of Operation and Comprehensive Loss

(unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2024     2023     2024     2023  

Revenue

         

Collaboration revenue

    $ —      $ 3,497     $ —      $ 4,487  

License and development support revenue

      —        —        251       —   
  

 

 

    

 

 

    

 

 

    

 

 

  

Total revenue

      —        3,497       251       4,487  
  

 

 

    

 

 

    

 

 

    

 

 

  

Operating expenses:

         

Research and development

      12,333       11,262       23,488       26,033  

General and administrative

      3,857       4,059       7,444       7,965  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

      16,190       15,321       30,932       33,998  
  

 

 

    

 

 

    

 

 

    

 

 

  

Loss from operations

      (16,190 )      (11,824 )      (30,681 )      (29,511 ) 

Other income (expense)

         

Interest income

      676       509       1,326       1,533  

Change in fair value of SAFEs

      (2,352 )      —        (2,620 )      —   

Other income (expense), net

      23       31       169       (23 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Total other income (expense)

      (1,653 )      540       (1,125 )      1,510  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    $ (17,843 )    $ (11,284 )    $ (31,806 )    $ (28,001 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss per share, basic and diluted

    $ (22.00 )    $ (14.09 )    $ (39.24 )    $ (35.12 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Weighted-average common shares outstanding, basic and diluted

      811,210       800,889       810,484       797,403  
  

 

 

    

 

 

    

 

 

    

 

 

  

Comprehensive loss:

         

Net Loss

    $ (17,843 )    $ (11,284 )    $ (31,806 )    $ (28,001 ) 

Other comprehensive income (loss)

      (86 )      127       (187 )      127  
  

 

 

    

 

 

    

 

 

    

 

 

  

Comprehensive loss

    $ (17,929 )    $ (11,157 )    $ (31,993 )    $ (27,874 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Contacts

Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

EX-101.SCH 3 artv-20240829.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 artv-20240829_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 artv-20240829_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document and Entity Information
Aug. 29, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001817241
Document Type 8-K
Document Period End Date Aug. 29, 2024
Entity Registrant Name Artiva Biotherapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-42179
Entity Tax Identification Number 83-3614316
Entity Address, Address Line One 5505 Morehouse Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 267-4467
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol ARTV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports artv-20240829.xsd artv-20240829_lab.xml artv-20240829_pre.xml d890088d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d890088d8k.htm": { "nsprefix": "artv", "nsuri": "http://imetrix.edgar-online.com/20240829", "dts": { "schema": { "local": [ "artv-20240829.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "artv-20240829_lab.xml" ] }, "presentationLink": { "local": [ "artv-20240829_pre.xml" ] }, "inline": { "local": [ "d890088d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-08-29_to_2024-08-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d890088d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-08-29_to_2024-08-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d890088d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://imetrix.edgar-online.com//20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-24-209920-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-209920-xbrl.zip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end XML 16 d890088d8k_htm.xml IDEA: XBRL DOCUMENT 0001817241 2024-08-29 2024-08-29 false 0001817241 8-K 2024-08-29 Artiva Biotherapeutics, Inc. DE 001-42179 83-3614316 5505 Morehouse Drive Suite 100 San Diego CA 92121 (858) 267-4467 false false false false Common Stock, $0.0001 par value per share ARTV NASDAQ true false